CEL-SCI公司正通过一项双轨战略，推进其头颈癌免疫疗法Multikine®的研发与商业化进程。该战略一方面聚焦于在美国开展一项关键性的注册研究，旨在为产品上市铺平道路；另一方面，公司积极布局沙特阿拉伯市场，寻求新的商业机会。这一举措标志着该公司在拓展其核心肿瘤免疫治疗产品全球影响力的道路上迈出了重要步伐。
CEL-SCI公司正通过一项双轨战略，推进其头颈癌免疫疗法Multikine®的研发与商业化进程。该战略一方面聚焦于在美国开展一项关键性的注册研究，旨在为产品上市铺平道路；另一方面，公司积极布局沙特阿拉伯市场，寻求新的商业机会。这一举措标志着该公司在拓展其核心肿瘤免疫治疗产品全球影响力的道路上迈出了重要步伐。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.